Second-line treatment with dasatinib in patients resistant to imatinib can select novel inhibitor-specific BCR-ABL mutants in Ph+ ALL
Loading...
Date
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Description
Keywords
Citation
Collections
Source
The Lancet Oncology